Suven Life surges 5.5% on neurological drug patent boost
Shares of Suven Life Sciences
soared 5.5 per cent today after the company received a patent
from New Zealand for a drug used for treatment of neuro-
The stock climbed 5.50 per cent to settle at Rs 190.95 on
BSE. During the day, it jumped 9.83 per cent to Rs 198.80.
On NSE, shares of the company advanced by 5.44 per cent
to close at Rs 190.75.
In terms of equity volume, 3.29 lakh shares of the
company were traded on BSE and over 21 lakh shares changed
hands on NSE during the day.
In a BSE filing today, Suven Life said it has been
granted "one product patent from New Zealand corresponding to
the New Chemical Entities (NCEs) for the treatment of
disorders associated with neuro-degenerative diseases".
The patents are valid till 2034, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by
the grant of these patents to Suven for our pipeline of
molecules in the CNS arena, which are being developed for
cognitive disorders with high unmet medical need with a huge
market potential globally."
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.